Canada’s EndoCeutics Lowers IPO Price to $7-$9

May 10, 2007 |

1 min read

WASHINGTON, May 9 (Reuters) - Canada's EndoCeutics Inc., a pharmaceutical firm, lowered the price of its planned initial public offering to between $7 and $9 per share from between $11-$13 each.

>>> Discuss This Story

IPO

MORE ON THIS TOPIC

Glowing red up arrow surrounded by dollar signs in black background. Illustration of the concept of positive return on investment and business earnings

IPO

Neuroscience Biotech LB Files for $228M IPO To Support Phase III Plans

September 9, 2025

·

1 min read

·

Annalee Armstrong

Changing or transforming, turning around, challenging the odds and conquering adversity, a businessman pole vaulting from the down arrow to the up arrow of growth

IPO

SPACs Line Up To Clear Biotech’s IPO Backlog

September 3, 2025

·

6 min read

·

Annalee Armstrong

A hand about to burst a money bubble with a pin. Metaphor for an economic or financial bubble crisis.

IPO

After 2021 SPAC Bubble, How Did These 6 Biotechs Fare?

September 3, 2025

·

10 min read

·

Tristan Manalac

A red paper airplane with a fighter jet shadow changes course from a group of other paper airplanes, a concept of different business and social behaviors. Vector illustration.

IPO

After Short Stint as a Private Company, BBOT Leaves SPAC Process Ready To Execute

September 3, 2025

·

3 min read

·

Annalee Armstrong